Cardiac Myxomas in Carney Complex: Single Institution Multidecade Experience
Defne Gunes Ergi1, Kyle W Klarich2, Joseph J Maleszewski3
1Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.
The Annals of Thoracic Surgery
|August 22, 2024
Summary
Cardiac myxomas affect over 60% of Carney complex (CNC) patients, with over half experiencing recurrence. Regular echocardiograms and surgical removal are key for managing these tumors in CNC patients.
Area of Science:
- Cardiology
- Oncology
- Genetics
Background:
- Carney complex (CNC) is a rare genetic disorder associated with multiple tumors.
- Cardiac myxomas are a significant manifestation of CNC.
- This study details the surgical experience with cardiac myxomas in CNC patients.
Purpose of the Study:
- To present the surgical experience with cardiac myxomas in patients with Carney complex.
- To analyze the incidence, characteristics, recurrence patterns, and outcomes of cardiac myxomas in CNC.
- To evaluate the long-term survival and recurrence-free survival after surgical management.
Main Methods:
- Retrospective review of institutional data for patients diagnosed with Carney complex (CNC).
- Data collection included clinical, surgical, and recurrence information from electronic medical records (1970-2023).
- Analysis of 38 CNC patients, focusing on the 24 who developed cardiac myxomas.
Main Results:
- Cardiac myxomas occurred in 63.1% of CNC patients, with a median age of onset at 39 years.
- The majority of myxomas were found in the left atrium (52.7%).
- Over half (54.1%) of patients experienced recurrence, with a median time to first recurrence of 7.5 years. Freedom from tumor recurrence was 16.7% at 10 years. Long-term survival was 100% at 10 and 15 years.
Conclusions:
- Cardiac myxomas are highly prevalent in Carney complex patients, with a substantial recurrence rate.
- Consistent echocardiographic monitoring is crucial for early detection of primary and recurrent cardiac myxomas.
- Surgical excision remains the primary therapeutic strategy for cardiac myxomas in the context of CNC.


